貝康醫療-B(2170.HK)盤中拉昇漲超8%
格隆匯5月25日丨貝康醫療-B(2170.HK)午後明顯走高,一度漲8.45%報26.3港元,市值72億港元。貝康醫療是中國輔助生殖基因檢測解決方案的領先創新平台,擁有首家及唯一獲國家藥品監督管理局(NMPA)許可第三代體外人工受孕(IVF)基因測試套裝(PGT-A)。花旗此前發報吿首予該股買入評級,目標價40港元。另外,近喬傑院士團隊近日建議推進輔助生殖人羣新冠疫苗接種,業內人士認為此舉能夠有效刺激具有生育意願、輔助生殖及相關服務需求人羣的生育計劃實施,打消育齡夫婦對新冠疫苗安全性的不必要擔憂,促進輔助生殖及基因檢測市場恢復,加快市場滲透率提升,貝康醫療有望受益。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.